Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : International Isotopes (INIS) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Belanger who wrote (9)	2/21/1998 5:04:00 PM
From: Vector1	Respond to of 81

Rick, I have not been following the company. Anything in the public filings. V1

To: Richard Belanger who wrote (9)	2/28/1998 11:02:00 AM
From: RRICH4	Read Replies (3) \| Respond to of 81

Research report from The GARP Monitor on INIS: This report is the catalyst that has caused INIS to sky rocket over the last couple of weeks. In it, the analyst says that INIS could become the preferred supplier of radioisotopes for the treatment of cancer and other serious diseases. INIS's competitive advantages are expected to include low cost production (about one-fifth those of that of cyclotrons), its unique LINAC (linear accelerator), purchased from the now defunct Super Collider in Texas, and it's energy level and beam intensity vastly exceeds that of other commercial accelerators. INIS is expected to begin production in Q2 of 1998. It is expected that INIS will be profitable beginning in Q4 1998, earn $0.40 for the year and EARN $1.50 PER SHARE in 1999, on revenues of $40 million once the LINAC is in full production. Management has wide ranging expert experience in the industry, put $7.5 million of their own money into the LINAC, and purchased 10% of the IPO. The company plans on to build an additional 3 to 7 LINACs in the next 10 years, mostly in international locations. These placements are expected to occur in deals with local partners that involve large up-front payments, ongoing royalties of at least 10%, and long term operating contracts. There are a slew of products in many phases of clinicals which make use of a wide variety of radionuclides. Almost all of them employ antibodies or other chemical entities tagged with with radioisotopes to attack cancer or other diseases. The radioisotope in therapeutic doses can be 10 to 100 times as high as in diagnostics. This implies there will be explosive demand for the more esoteric isotopes that ONLY THE COMPANY'S LINAC CAN MAKE IN QUANTITY.